Roche's personalised medicine entrectinib shrank tumours in people with NTRK solid tumours
Roche announced results from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials that showed the investigational personalised medicine entrectinib shrank tumours (ORR) in more than half (57.4%) of people with NTRK fusion-positive solid tumours. October 21, 2018